United States · Platforms & data · Stocktwits

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Published by Stocktwits · United States 8 h ago

Iovance Biotherapeutics (IOVA) was in the spotlight on Friday after the biotech firm reported promising results from a Phase 2 trial of its experimental cell therapy Lifileucel,…

Read the full article on Stocktwits Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)

Also worth reading

The Motley Fool

American Express: 3 Key Takeaways for Long-Term Investors

MarketBeat

Genmab A/S (NASDAQ:GMAB) Stock Price Up 7.4% - What's Next?

Seeking Alpha

Flagstar forecasts 2027 EPS of $0.85-$0.95 and shifts full turnaround timeline to 2028 amid higher rates

MarketWatch

‘Some people did everything right’: I lost my home in the Great Recession. I rent in my 50s. Why is that judged as failure?

Investing.com

Jana Small Finance Bank Q2 FY27 slides: record profit drives guidance upgrade

Benzinga